Cleerly has had a busy few months – attending conferences, panel sessions, and winning awards as we all work together to achieve our mission of a world without heart attacks. We’re proud of the work our teams have accomplished, making waves with our groundbreaking innovations and commitment to revolutionizing cardiovascular care.
Recent Highlights:
We were thrilled when our contributions to the AI health tech sector were acknowledged with CEO and Founder, Dr. James K. Min being named to the inaugural Business Insider AI 100 list! This recognition is a testament to our relentless pursuit of innovation and the exceptional work of our talented team as we continue to leverage AI and machine learning to identify those at risk of heart attacks.
We had the honor of returning to HLTH in Las Vegas again this year, with Dr. Min participating as a panelist in the “Heart Disease, Too Long at the Top” panel discussion with other cardiologists and leaders in the heart health space. During the panel, Dr. Min shared his expertise on the factors contributing to heart disease being the leading cause of death, shedding light on our commitment to tackling heart disease head on with the goal of creating a heart attack-free world.
Additionally, we were on the showroom floor throughout the conference, showcasing our cutting-edge solutions as an exhibitor in the HLTH Innovation Pavilion. We loved getting to meet with so many leaders in digital health!
A successful week at HLTH concluded with winning the “Best Use of AI in Health Tech” Award in the Best in Class category of the Digital Health Hub Foundation Digital Health Awards. Our CEO and Founder, Dr. Min, accepted the award on behalf of Cleerly at HLTH in Las Vegas, joined by Chief Scientific Officer, Udo Hoffmann, MD, MPH, Chief Financial Officer, Krissy Wright, and our sales leads, Keith Irby and Barry Klegerman. It is a huge accomplishment being selected from over 1,500 companies worldwide and over 450 competitors in our category.
At the 28th Annual Phoenix Conference, we were named a finalist for the 2023 Most Promising New Product Award. This accolade celebrates remarkable successes in the medical device and diagnostic industry. At the event, Dr. Min partook in the panel titled "Medtech Moneyball: Leveraging Real-World Data to Optimize Product Portfolios, Clinical Trials, Reimbursement, and Commercial Execution" and discussed how medtech corporations are taking advantage of real-world data to enhance their operations.
We’re incredibly proud of our recent accomplishments and event participation, which truly highlight our unwavering dedication to transforming cardiovascular care through AI. As we close out 2023, we are excited to reflect on our achievements and the impact we have made, and we are even more thrilled about what lies ahead. With our commitment to innovation and the remarkable progress we have already made, there is still more to come as we continue to lead the charge in making a meaningful difference in the lives of patients and the healthcare industry as a whole through the use of AI technology.